MyFinsight

HomeBlogAboutContact

MyFinsight

Making company financials insightful for everyone

Quick Links

  • About
  • Blog
  • Contact

Follow Us

  • X.com
  • Thread
  • Instagram

© 2026 MyFinsight. All rights reserved.

|||

For the quarter ending 2025-09-30, CARL had $81,901K increase in cash & cash equivalents over the period. -$8,618K in free cash flow.

Cash Flow Overview

Change in Cash
$81,901K
Free Cash flow
-$8,618K

Unit: Thousand (K) dollars (except for numbers of shares and EPS)
Cash Flow
2025-09-30
2025-06-30
Net loss
-8,526 -12,495
Depreciation and amortization
82 101
Stock-based compensation
704 433
Non-cash interest
55 108
Loss on remeasurement of warrant liabilities
65 270
Non-cash lease expense
157 219
Provision for credit losses
24 338
Provision for excess and obsolete inventory
465 872
Other non-cash items
-17 -
Accounts receivable, net
1,611 3,282
Inventory
736 945
Prepaid expenses and other assets
1,638 500
Accounts payable
682 1
Accrued liabilities
608 -78
Accrued compensation
1,296 -157
Lease liabilities
-103 -82
Net cash used in operating activities
-8,459 -15,197
Purchase of property and equipment
159 410
Capitalized internal use software costs
184 374
Payment of initial direct costs related to operating leases
0 126
Net cash used in investing activities
-343 -910
Proceeds from initial public offering, net of underwriting discounts and commissions
93,465 -
Payments for deferred initial public offering costs
2,763 2,648
Proceeds from issuance of series c convertible preferred stock, net of issuance costs
0 11,919
Proceeds from exercises of stock options
1 183
Net cash provided by financing activities
90,703 9,454
Increase in cash, cash equivalents, and restricted cash
81,901 -6,653
Cash and cash equivalents at beginning of period
40,225 -
Cash and cash equivalents at end of period
115,473 -
Unit: Thousand (K) dollars

Time Plot

Show the time plot by selecting a row from the table.

CARLSMED, INC. (CARL)

CARLSMED, INC. (CARL)